INTRODUCTION {#sec1-1}
============

Around 53--63% of patients with community-acquired pneumonia (CAP) are hospitalized every year.\[[@ref1]\] There has been a growing concern for an increase in methicillin-resistant *Staphylococcus aureus* (MRSA) pneumonia. Traditionally MRSA was a concern for nosocomial pneumonia, but as the rate of MRSA has increased in the community setting, this organism is now starting to be seen in patients without risks for healthcare-associated pneumonia.\[[@ref2][@ref3][@ref4]\] In addition, MRSA isolates carrying Panton--Valentine leukocidin genes were associated with severe pneumonia resulting in death.\[[@ref2]\] The Infectious Disease Society of America recently recommended adding vancomycin to the standard antibiotic coverage (respiratory fluoroquinolones or a beta-lactam plus a macrolide) for patients admitted with CAP severe enough to warrant intensive care unit (ICU) admission.\[[@ref5]\] Often times, due to the severity of illness and need for ICU admission, many physicians also prescribe antibiotics to cover *Pseudomonas aeruginosa* despite the absence of structural lung disease. The objective of the study was to evaluate the prevalence of MRSA and *P. aeruginosa* and factors associated with failure of therapy.

METHODS {#sec1-2}
=======

Electronic charts of patients with *International Classification of Diseases*, *Ninth Revision* (ICD 9) codes of pneumonia who were admitted to the Medical and Surgical ICU at Banner University of Arizona Medical Center (Tucson Campus), a tertiary medical center, from November 2013 through December 2016 were reviewed by the research team. Inclusion criteria included patients who were aged 18 years or older and admitted to the ICU in the first 48 hours of presentation to the hospital with a diagnosis of pneumonia. Patients were excluded if they had risk factors for healthcare-associated pneumonia, including residence in a nursing home or extended care facility, home infusion therapy, chronic dialysis within the last 30 days, home wound care, immunosuppressive disease or therapy, or hospitalization in the last 90 days. Patients who were pregnant, incarcerated, or ventilator dependent were also excluded. The protocol was approved by the University of Arizona Institutional Review Board.

The entire population was used to evaluate factors associated with MRSA pneumonia and poor outcome. Failure was defined as death attributed to pneumonia, patient intubated more than 48 hours after admission to ICU, need for antibiotic escalation, or readmission attributed to pneumonia. "Any failure" was defined as all-cause mortality, patient intubated more than 48 hours after admission to ICU, need for antibiotic escalation, or readmission for any reason. Factors evaluated for association with poor outcome included demographics, signs and symptoms including chest X-ray findings, and medical history (chronic obstructive pulmonary disease \[COPD\], diabetes, prior antibiotic exposure within 30 days, history of MRSA or pseudomonal infection, or positive MRSA nasal swab within 90 days). The populations of MRSA pneumonia (case and control) were composed of a subset of the entire population. MRSA case subjects had a respiratory culture positive for MRSA during their hospital stay. Subjects included in the MRSA control group had to have a respiratory specimen available that was negative for MRSA and/or a negative MRSA nasal swab. The case and control groups were used to assess potential factors associated with MRSA pneumonia. A similar process was planned for *P. aeruginosa* pneumonia except the absence of a surrogate marker comparable to the MRSA nasal swab.

Fisher exact test was used to identify factors associated with outcomes or pneumonia type. Classification factors associated with *P* values \<0.2 were further evaluated using multivariate logistic regression. To be retained as a predictive factor, the *P* value in the final model was needed to be \<0.05.

Statistical analysis was performed with SAS version 9.4 (SAS Institute, Cary, NC). Procedure FREQ was used to evaluate differences in proportions with the Fisher option. A *t* test or Wilcoxon test was used to evaluate differences in age, ICU length of stay, and follow-up times. Logistic regression was performed with factors identified (*P* \< 0.2) by the univariate results. Both forward and backward stepwise procedures were used to ensure model stability.

RESULTS {#sec1-3}
=======

A total of 1065 charts were identified using ICD 9 codes for pneumonia and admission to the ICU. Of these, only 209 patients met appropriate inclusion criteria. The cohort consisted of 104 (49.8%) males and 105 (50.2%) females, predominately white (79.5%) and non-Hispanic (69.7%).

Comorbidities, clinical presentation, microbiology, radiology, and antibiotics prescribed are presented in [Table 1](#T1){ref-type="table"}. The most common comorbidity was COPD (31.1%). Dyspnea was the most common presenting symptoms (83.4%). A total of 117 patients (56%) had a respiratory specimen performed \[[Table 1](#T1){ref-type="table"}\], out of which 39 were positive (33.3%). A total of 60 nasal swab MRSA polymerase chain reaction (PCR) tests were performed and only 11 had positive results (18.3%). The most common bacterial cause of pneumonia was *Streptococcus pneumoniae*. Only seven patients had MRSA (five from sputum and two from tracheal aspirate) and one patient had *P. aeruginosa* (from tracheal aspirate). Notably only three patients had MRSA bacteremia with no cases of *P. aeruginosa* bacteremia. A total of 124 cases had negative respiratory specimen and/or MRSA nasal swab (control cases). There were seven cases of MRSA pneumonia. A total of 113 patients (54.1%) received anti-MRSA therapy, 122 (58.4%) received antipseudomonal therapy, and 164 (78.5%) received atypical coverage.

###### 

Comorbidities, clinical presentation, microbiology, and antibiotic prescription (*N* = 209)

  Parameter                        All Subjects      MRSA---case/control populations                     
  -------------------------------- ----------------- --------------------------------- ----------------- --------
  Age---mean (SD)                  61.5 (17.5)       54.1 (15.1)                       61.5 (17.5)       \>0.2
  Sex (female)                     104/209 (49.8%)   3/7 (42.9%)                       65/124 (52.4%)    \>0.2
  Ethnicity (Hispanic)             63/208 (30.3%)    1/7 (14.3)                        39/124 (31.5%)    \>0.2
  Race (white)                     163/205 (79.5%)   6/7 (85.7%)                       102/123 (82.9%)   \>0.2
  Recent influenza                 3/209 (1.44%)     0/7 (0.00%)                       2/124 (1.61%)     \>0.2
  Recent antibiotics               26/206 (12.6%)    1/7 (14.3%)                       17/123 (13.8%)    \>0.2
  Diabetes                         29/191 (15.2%)    1/6 (16.7%)                       17/116 (14.7%)    \>0.2
  COPD                             61/196 (31.1%)    2/6 (33.3%)                       40/118 (33.9%)    \>0.2
  History of MRSA                  1/209 (0.48 %)    1/7 (14.3%)                       0/124 (0.00%)     0.0534
  Respiratory specimen                                                                                   
  BAL                              21 (10.1%)        0 (0.00%)                         21 (16.9%)        
  Sputum                           71 (34.0%)        5 (71.4%)                         64 (51.6%)        \>0.2
  Trach aspiration                 25 (12.0%)        2 (28.6%)                         20 (16.1%)        
  Not available                    92 (44.0%)        0 (0.00%)                         19 (15.3%)        
  Positive MRSA nasal swab         11/60 (18.3%)     4/4 (100%)                        0/49 (0.00%)      ---
  Positive blood culture           30/202 (14.9%)    3/7 (42.9%)                       18/123 (14.6%)    0.0831
  Coccidioidomycosis               8/112 (7.14%)     1/6 (16.7%)                       3/69 (4.35%)      \>0.2
  Positive respiratory PCR panel   13/104 (12.5%)    0/1 (0.00%)                       10/72 (13.9%)     \>0.2
  Positive influenza PCR           14/117 (12.0%)    0/2 (0.00%)                       12/78 (15.4%)     \>0.2
  Cough                            133/204 (65.2%)   3/7 (42.9%)                       80/120 (66.7%)    \>0.2
  Fever                            63/203 (31.0%)    5/7 (71.4%)                       39/122 (32.0)     0.0452
  Hypotension                      45/200 (22.5%)    3/7 (42.9%)                       28/120 (23.3%)    \>0.2
  Dyspnea                          171/205 (83.4%)   5/7 (71.4%)                       104/122 (85.2%)   \>0.2
  CXR---necrotizing pneumonia      3/209 (1.44%)     1/7 (14.3%)                       1/124 (0.81%)     0.104
  CXR---effusion                   57/209 (27.3%)    4/7 (57.1%)                       30/124 (24.2%)    0.0741
  CXR---multilobular               105/209 (50.2%)   5/7 (71.4%)                       68/124 (54.8%)    \>0.2
  Antibiotics \> 48 h              197/207 (95.2%)   7/7 (100%)                        119/123 (96.8%)   \>0.2
  Anti-MRSA antibiotic             113/209 (54.1%)   6/7 (85.7%)                       70/124 (56.5%)    \>0.2
  Antipseudomonal antibiotic       122/209 (58.4%)   6/7 (85.7%)                       73/124 (58.9%)    \>0.2
  Atypical coverage                164/209 (78.5%)   6/7 (85.7%)                       102/124 (82.3%)   \>0.2
  Readmission                      63/208 (30.3%)    3/7 (42.9%)                       34/124 (27.4%)    \>0.2
  Readmission d/t pneumonia        27/205 (13.2%)    2/7 (28.6%)                       17/123 (13.8%)    \>0.2
  CDI within 6 months              8/208 (3.85%)     0/7 (0.00%)                       5/124 (4.03%)     \>0.2
  Intubation after 48 h            16/207 (7.73%)    0/7 (0.00%)                       12/124 (9.68%)    \>0.2
  Antibiotic escalated             17/208 (8.17%)    1/7 (14.3%)                       12/124 (9.68%)    \>0.2
  Death                            29/207 (14.0%)    1/7 (14.3%)                       18/123 (14.6%)    \>0.2
  Death due to pneumonia           20/207 (9.66%)    0/7 (0.00%)                       13/123 (10.6%)    \>0.2
  ICU length of stay (days)        3 (0--50)         7 (3--15)                         3 (2--7)          0.0471
  Follow-up duration (days)        180 (1--180)      180 (84--180)                     180 (17--180)     \>0.2

MRSA = methicillin-resistant *Staphylococcus aureus*, ICU = intensive care unit, COPD = chronic obstructive pulmonary disease, BAL = bronchoalveolar lavage, CXR = chest X-ray, CDI = *Clostridium difficile* infection, SD = standard deviation, PCR = polymerase chain reaction

Independent factors associated with MRSA pneumonia on the univariate analysis (*P* \< 0.2) included history of MRSA (*P* = 0.053), positive blood culture (*P* = 0.083), fever (*P* = 0.045), necrotizing pneumonia (*P* = 0.104), effusion (*P* = 0.0741), and ICU length of stay (*P* = 0.047) \[[Table 1](#T1){ref-type="table"}\]. Only effusion (*P* = 0.001) and fever (*P* = 0.002) were associated with MRSA pneumonia in the multivariate logistic regression.

A total of 69 patients developed failure (33.0%) and 105 had any failure (50.2%). [Table 2](#T2){ref-type="table"} shows independent variables associated with these primary outcomes. Positive blood culture (*P* = 0.019), effusion (*P* = 0.100), receipt of antibiotics over 48 hours (*P* = 0.080), and receipt of antibiotics against atypical organisms (*P* = 0.033) were all associated with failure on the univariate analysis. Only positive blood culture (*P* = 0.010) was associated with failure on the multivariate logistic regression. Similarly, positive blood culture (*P* = 0.002) was the only independent factor associated with any failure on multivariate logistic regression.

###### 

Association between dependent variables and primary outcomes (failure and any failure)

  Characteristic                       Failure present (*n* = 69)   Failure absent (*n* = 140)   *P* value   Any failure present (*n* = 105)   Any failure absent (*n* = 104)   *P* value
  ------------------------------------ ---------------------------- ---------------------------- ----------- --------------------------------- -------------------------------- -----------
  Sex---female                         32/69 (46.4%)                71/140 (51.4%)               \>0.2       51/104 (49.0%)                    53/140 (50.5%)                   \>0.2
  Ethnicity---Hispanic                 18/69 (26.1%)                45/139 (32.4%)               \>0.2       28/104 (26.9%)                    35/104 (33.7%)                   \>0.2
  Race---white                         55/68 (80.9%)                108/137 (78.8%)              \>0.2       76/102 (74.5%)                    87/103 (84.7%)                   \>0.2
  Recent influenza                     2/69 (2.90%)                 1/140 (0.71%)                \>0.2       2/104 (1.92%)                     1/105 (0.95%)                    \>0.2
  Recent antibiotic                    61/69 (88.4%)                119/137 (86.9%)              \>0.2       13/103 (12.6%)                    13/103 (12.6%)                   \>0.2
  Diabetes                             7/66 (10.6%)                 22/125 (17.6%)               \>0.2       14/96 (14.6%)                     15/95 (15.8%)                    \>0.2
  COPD                                 20/64 (31.3%)                41/132 (31.1%)               \>0.2       24/95 (25.3%)                     37/101 (36.6%)                   0.0920
  History of MRSA                      1/69 (1.45%)                 0/140 (0.0%)                 \>0.2       1/104 (0.96%)                     0/105 (0.0%)                     \>0.2
  Nasal MRSA                           3/19 (15.8%)                 8/41 (19.5%)                 \>0.2       6/27 (77.8%)                      5/33 (84.9%)                     \>0.2
  Blood culture positive               16/67 (23.9%)                14/135 (66.8%)               0.0193      23/99 (23.2%)                     7/103 (6.80%)                    0.0013
  Coccidioidomycosis                   1/32 (3.13%)                 7/80 (8.75%)                 \>0.2       3/52 (5.77%)                      5/60 (8.33%)                     \>0.2
  Positive respiratory PCR             4/38 (10.5%)                 9/66 (13.6%)                 \>0.2       6/53 (11.3%)                      7/51 (13.7%)                     \>0.2
  Positive influenza PCR               4/40 (10.0%)                 10/77 (13.0%)                \>0.2       5/55 (9.09%)                      9/62 (14.5%)                     \>0.2
  CXR---necrotizing                    1/69 (1.45%)                 2/140 (1.43%)                \>0.2       2/104 (1.92%)                     1/105 (0.95%)                    \>0.2
  CXR---effusion                       24/69 (34.8%)                39/140 (27.9%)               0.0997      36/104 (34.6%)                    27/105 (25.7%)                   0.177
  CXR---multilobular                   37/69 (53.6%)                72/140 (51.4%)               \>0.25      52/104 (50.0%)                    57/105 (54.3%)                   \>0.2
  Cough                                42/67 (62.7%)                91/137 (66.4%)               \>0.2       62/101 (61.4%)                    71/103 (68.9%)                   \>0.2
  Fever                                22/66 (33.3%)                41/137 (29.9%)               \>0.2       29/100 (29.0%)                    34/103 (33.0%)                   \>0.2
  Hypotension                          18/66 (27.3%)                27/134 (20.2%)               \>0.2       27/99 (27.3%)                     18/101 (17.8%)                   0.129
  Dyspnea                              58/67 (86.6%)                113/138 (67.3%)              \>0.2       87/101 (86.1%)                    84/104 (80.8%)                   \>0.2
  Antibiotics \> 48 h                  61/67 (91.0%)                136/140 (67.3%)              0.0803      94/102 (92.2%)                    103/105 (98.1%)                  0.0562
  Anti-MRSA antibiotics                38/69 (55.1%)                75/140 (53.6%)               \>0.2       55/104 (47.1%)                    47/105 (44.8%)                   \>0.2
  Antipseudomonal antibiotics          41/69 (59.4%)                65/140 (46.4%)               \>0.2       61/104 (58.7%)                    61/105 (58.1%)                   \>0.2
  Anti-atypical organism antibiotics   48/69 (69.6%)                81/140 (57.9%)               0.0326      75/104 (72.1%)                    89/105 (84.8%)                   0.0294

MRSA = methicillin-resistant *Staphylococcus aureus*, COPD = chronic obstructive pulmonary disease, CXR = chest X-ray, PCR = polymerase chain reaction

DISCUSSION {#sec1-4}
==========

In our study, we found that overprescription of antibiotics in the ICU for patients with CAP remains a significant problem. Antipseudomonal coverage and anti-MRSA coverage were often prescribed in this population (58.4% and 54.1%, respectively). Antipseudomonal coverage was rarely necessary as pseudomonal pneumonia was found in only one case (0.9%). This patient did not have history of COPD or bronchiectasis. MRSA was found in only 6.0% of the cases. We found that lack of antipseudomonal and anti-MRSA coverage was not associated with higher rates of primary outcomes (failure or any failure).

Our study does not support the routine use of antipseudomonal and anti-MRSA therapy for patients with CAP in the ICU given low prevalence. It may be necessary to use anti-MRSA therapy in selected patients (e.g., with hypotension, necrotizing pneumonia, and positive nasal swab MRSA PCR).\[[@ref5][@ref6]\] Recent data were published regarding the negative predictive value of a negative nasal swab MRSA PCR. Two studies by Dangerfield *et al*.\[[@ref7]\] and Giancola *et al*.\[[@ref6]\] have shown that a negative nasal swab MRSA PCR indicates the absence of MRSA pneumonia in patients with low MRSA incidence and this test might be used to deescalate antibiotics in cases of negative culture.

Our study has several limitations. It is retrospective in nature and was performed in one center in Southwestern United States, which limits the generalizability of our findings. In addition, only 113 patients (54%) had respiratory culture performed and 90 (43%) had a nasal swab MRSA PCR performed in the previous 90 days. We did not assess timing of antibiotics, which could impact culture and nasal swab data.

Future directions include looking at a larger population subset and further defining populations needing broad-spectrum antibiotics to prevent antibiotic resistance.
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